台灣臨床試驗主持人資料庫|TPIDB

2018-11-15 - 2020-12-31

Phase III

Completed

A Phase 3 Randomized Withdrawal, Double Blind, Placebo Controlled, Multi Center Study Investigating the Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over, with Moderate to Severe Atopic Dermatitis with the Option of Rescue Treatment in Flaring Subjects

Condition/Disease

Atopic Dermatitis
Test Drug

PF-04965842

Participate Sites
6Sites

Terminated6Sites

李婉若

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2018-11-02 - 2028-12-31

Phase III

Active

A Phase III, Double-blind, Placebo controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)

Condition/Disease

Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer
Test Drug

Durvalumab (MEDI4736)

Participate Sites
9Sites

Recruiting6Sites

Terminated3Sites

李岡遠

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

郭漢彬

Taipei Medical University Hospital

Division of Thoracic Medicine

2018-12-01 - 2024-12-31

Phase III

Active

A Phase III, Randomised,Double-Blind,Placebo-Controlled,Study of Durvalumab as Consolidation Therapy in Patients With Locally Advanced,Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy

Condition/Disease

Non-Small Cell Lung Cancer
Test Drug

Durvalumab (MEDI4736)

Participate Sites
7Sites

Recruiting3Sites

Terminated4Sites

李岡遠

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2016-12-29 - 2023-09-28

Phase III

Completed

A Phase III Trial of Chidamide in Combination with Exemestane in Patients with Hormone Receptor-Positive Advanced Breast Cancer (ACE)

Condition/Disease

Hormone Receptor-Positive Advanced Breast Cancer
Test Drug

NA

Participate Sites
9Sites

Recruiting6Sites

Terminated2Sites

趙祖怡

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

劉良智

China Medical University Hospital-Taipei

未分科

2016-06-01 - 2019-12-31

Phase I

Completed

A Phase 2 Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer

Condition/Disease

Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer
Test Drug

1. Abemaciclib 2. Pembrolizumab

Participate Sites
4Sites

Terminated4Sites

趙祖怡

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

2017-09-01 - 2021-12-31

Phase I

An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007